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Muscarinic acetylcholine receptors (mAChRs) are expressed in several primary and metastatic tumours. ACh 
synthesized by the tumour cells can modulate cell proliferation by an autocrine mechanism which involves 
cholinergic receptors. Although a direct or indirect role of transduction pathways activated by cholinergic receptors 
has not yet been demonstrated, the inhibition of ACh synthesis as well as the release or use of cholinergic antagonists 
are able to counteract tumour cell growth and slow down the tumour progression in small cell lung carcinoma [1]. In 
mammary adenocarcinoma and melanoma cell lines, mAChRs can also modulate cell migration and angiogenesis, 
suggesting their involvement in the metastases formation [2]. The characterization of mAChR effects on more 
aggressive brain tumours is still poorly investigated. Glioblastomas are the most common brain tumours in humans. 
Recently, Tata et al. demonstrated that M2 receptor activation inhibits glioma cell growth and survival, suggesting 
that this receptor subtype may represent a new putative target for glioblastoma therapy [3,4]. Therefore, the 
identification of more selective ligands for M2 mAChRs may be of clinical significance. Here we report the results 
on the effects of the muscarinic orthosteric superagonist Iperoxo [5] and its related dualsteric agonists P-6-Iper and 
N-8-Iper [6]. Our data demonstrate that cell proliferation as well as cell survival of the U251 and U87 stable cell 
lines were unaffected by treatment with Iperoxo and P-6-Iper. Conversely, N-8-Iper decreased cell proliferation in a 
time and dose dependent manner. Similarly, N-8-Iper (100 M) was also able to counteract cell proliferation in 
glioblastoma cancer stem cells (GB7) obtained from human biopsy. The antiproliferative effect shown by N-8-Iper 
was significantly counteracted by the selective M2 antagonist methoctramine (10
7
 M), suggesting an actual 
contribution of the M2 selective activation. 
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